Stocktoria
GYRE THERAPEUTICS, INC. GYRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2006-04-12
GYRE THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M |
| Gross profit | — | $101.9M | $108.8M | $97.5M | — |
| R&D expense | $13.7M | $12.0M | $13.8M | — | $68.9M |
| Operating income | $11.5M | $16.2M | -$67.2M | $9.2M | -$87.9M |
| Income tax | $4.6M | $5.3M | $8.5M | $5.1M | — |
| Net income | $9.9M | $17.9M | -$85.5M | $4.3M | -$87.9M |
| EPS (diluted) | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 |
| Operating cash flow | $1.0M | -$3.6M | $25.9M | $10.7M | -$83.8M |
| Free cash flow | -$180,000 | -$6.0M | $17.4M | $5.7M | -$84.6M |
| Cash & equivalents | $37.1M | $11.8M | $33.5M | $25.2M | $44.3M |
| Inventory | $10.2M | $6.3M | $4.3M | $6.1M | — |
| Total assets | $166.1M | $125.4M | $116.5M | $84.8M | $55.7M |
| Total liabilities | $23.9M | $27.0M | $38.1M | $12.5M | $14.6M |
| Shareholders' equity | $142.3M | $98.4M | -$15.8M | $72.2M | $59.5M |
Source: SEC EDGAR filings · CIK 0001124105 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.